Shahram Seyedin-Noor

Founder General Partner @Civilization Ventures

Civilization Ventures (inquiries to i•••@civilizationventures.com) invests in visionary founders that are leading the future of health tech and biology-driven innovation. We are mentor capitalists who aim to be the first check and lead investor in highly disruptive companies in three main categories: synthetic biology (gene editing, gene/cell therapies, regenerative medicine, DNA computing), diagnostics (NGS, genomics, devices), and digital health (AI/ML, virtual care). Our team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed. In 2022, we celebrated the acquisition of CRISPR gene editing pioneer Rewrite Therapeutics - where Shahram was lead investor and sat on the Board - by Intellia. We had our first \"unicorn\" exit in 2018 with the public listing of gene and cell therapy leader Rocket Pharma (NASDAQ: RCKT). CV is a pre/seed investor in some of the industry\'s leading startups, including Foresight Diagnostics (cancer MRD testing), Singular Bio (non-invasive prenatal testing - acq. by Invitae), BilliontoOne (prenatal and cancer testing), and Lemonaid Health (telemedicine, acq. by 23andme).